This is the
talk page for discussing improvements to the
Carbamazepine article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives: 1Auto-archiving period: 30 days |
This article is rated B-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Carbamazepine.
|
I noticed that someone added a {{ merge}} banner to Environmental fate and occurrence of carbamazepine suggesting its merge here. I support the merge. I don't think the topic of "Environmental fate and occurrence of carbamazepine" meets notability guidelines and therefore shouldn't be a standalone article. Much of the content in that article is background information about wastewater treatment and about carbamazepine. It is redundant to content at existing articles. The remaining content that is actually about the environmental fate could be transferred to the existing Environmental fate section already here in carbamazepine. 14:11, 12 December 2014 (UTC)
Hi,
I noticed that someone has re-written the section I wrote/edited on Pharmacogenetics. I am new to Wikipedia, so I apologize if I get any of the Wikipedia etiquette wrong, but I believe I was supposed to start a talk page about this instead of reverting the edits?
A few points to make about the new paragraph:
- The new paragraph has restricted citations to only the US FDA label. While I have no issue with the citing of this label, the paragraph now no longer paints a complete picture of the association between HLA-B *15:02 and carbamazepine. For one thing, the risk in some Asian populations can be up to ~2500 times higher in carriers of the allele, and is often at least above 20; stating that the risk is 10x higher is an understatement. The FDA has been somewhat slow to begin including pharmacogenetic information in their labels, and so while they may be accurate to an extent, often drug labels are not the best source for this type of information.
- An allele is not a form of a protein, it is a form of a gene. Additionally, HLA-B alleles are commonly written in the form *15:02, rather than 1502. Therefore the sentence more accurately should read "...who have a specific version of the HLA-B gene, namely the *15:02 allele..."
- The information from sources such as CPIC and CPDNS have been removed. The implementation of pharmacogenetics in clinical practice is an area of medicine that is relevant to many readers of the page and important in the scope of genetics, so I think these citations are important to leave in the article.
- Information on the other alleles associated with carbamazepine have been removed. These alleles are almost as important as *15:02 - since the *15:02 allele is rare in Caucasians and some Asian populations, any future genetic testing prior to carbamazepine treatment may done for alleles such as *31:01 and *15:11, since they are more common in particular populations.
I understand that there may have been particular Wikipedia-related reasons for why some content was removed - any information about this would be useful so I don't make mistakes on any future pages I contribute to. I also understand that short concise paragraphs are better than rambling ones, but in this case I believe we are now missing some important information about the drug.
Perhaps we can return some information to the page?
Thanks,
Jmbarbarino ( talk) 19:19, 5 January 2015 (UTC)
Made a few changes to the MoA section. Basically I removed the section that said carbamazepine stabilises the inactive state of VG sodium channels. — Preceding unsigned comment added by 213.104.127.138 ( talk) 16:56, 18 November 2016 (UTC)
This is the
talk page for discussing improvements to the
Carbamazepine article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives: 1Auto-archiving period: 30 days |
This article is rated B-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Carbamazepine.
|
I noticed that someone added a {{ merge}} banner to Environmental fate and occurrence of carbamazepine suggesting its merge here. I support the merge. I don't think the topic of "Environmental fate and occurrence of carbamazepine" meets notability guidelines and therefore shouldn't be a standalone article. Much of the content in that article is background information about wastewater treatment and about carbamazepine. It is redundant to content at existing articles. The remaining content that is actually about the environmental fate could be transferred to the existing Environmental fate section already here in carbamazepine. 14:11, 12 December 2014 (UTC)
Hi,
I noticed that someone has re-written the section I wrote/edited on Pharmacogenetics. I am new to Wikipedia, so I apologize if I get any of the Wikipedia etiquette wrong, but I believe I was supposed to start a talk page about this instead of reverting the edits?
A few points to make about the new paragraph:
- The new paragraph has restricted citations to only the US FDA label. While I have no issue with the citing of this label, the paragraph now no longer paints a complete picture of the association between HLA-B *15:02 and carbamazepine. For one thing, the risk in some Asian populations can be up to ~2500 times higher in carriers of the allele, and is often at least above 20; stating that the risk is 10x higher is an understatement. The FDA has been somewhat slow to begin including pharmacogenetic information in their labels, and so while they may be accurate to an extent, often drug labels are not the best source for this type of information.
- An allele is not a form of a protein, it is a form of a gene. Additionally, HLA-B alleles are commonly written in the form *15:02, rather than 1502. Therefore the sentence more accurately should read "...who have a specific version of the HLA-B gene, namely the *15:02 allele..."
- The information from sources such as CPIC and CPDNS have been removed. The implementation of pharmacogenetics in clinical practice is an area of medicine that is relevant to many readers of the page and important in the scope of genetics, so I think these citations are important to leave in the article.
- Information on the other alleles associated with carbamazepine have been removed. These alleles are almost as important as *15:02 - since the *15:02 allele is rare in Caucasians and some Asian populations, any future genetic testing prior to carbamazepine treatment may done for alleles such as *31:01 and *15:11, since they are more common in particular populations.
I understand that there may have been particular Wikipedia-related reasons for why some content was removed - any information about this would be useful so I don't make mistakes on any future pages I contribute to. I also understand that short concise paragraphs are better than rambling ones, but in this case I believe we are now missing some important information about the drug.
Perhaps we can return some information to the page?
Thanks,
Jmbarbarino ( talk) 19:19, 5 January 2015 (UTC)
Made a few changes to the MoA section. Basically I removed the section that said carbamazepine stabilises the inactive state of VG sodium channels. — Preceding unsigned comment added by 213.104.127.138 ( talk) 16:56, 18 November 2016 (UTC)